Analysts Anticipate OraSure Technologies, Inc. (OSUR) Will Post Earnings of $0.07 Per Share

Equities analysts expect OraSure Technologies, Inc. (NASDAQ:OSUR) to report earnings per share (EPS) of $0.07 for the current quarter, according to Zacks. Two analysts have provided estimates for OraSure Technologies’ earnings. OraSure Technologies also posted earnings of $0.07 per share during the same quarter last year. The business is expected to report its next earnings report on Wednesday, August 2nd.

According to Zacks, analysts expect that OraSure Technologies will report full-year earnings of $0.44 per share for the current financial year, with EPS estimates ranging from $0.40 to $0.47. For the next fiscal year, analysts expect that the business will report earnings of $0.31 per share, with EPS estimates ranging from $0.30 to $0.31. Zacks’ EPS calculations are an average based on a survey of research firms that follow OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 EPS for the quarter, topping the consensus estimate of $0.17 by $0.04. OraSure Technologies had a return on equity of 16.06% and a net margin of 22.57%. The business had revenue of $32.55 million during the quarter, compared to analysts’ expectations of $31.19 million. During the same quarter last year, the firm posted $0.04 earnings per share. The firm’s revenue was up 11.9% on a year-over-year basis.

A number of research analysts recently issued reports on the company. Jefferies Group LLC boosted their price target on OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, May 4th. Zacks Investment Research downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, April 12th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $12.04.

In other OraSure Technologies news, SVP Mark L. Kuna sold 36,413 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $15.11, for a total transaction of $550,200.43. Following the transaction, the senior vice president now owns 92,904 shares in the company, valued at approximately $1,403,779.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Douglas A. Michels sold 361,216 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $15.08, for a total value of $5,447,137.28. Following the transaction, the chief executive officer now owns 881,620 shares in the company, valued at approximately $13,294,829.60. The disclosure for this sale can be found here. Insiders have sold a total of 929,859 shares of company stock worth $13,926,644 in the last quarter. Company insiders own 7.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in OraSure Technologies by 127,593.4% in the first quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock worth $100,123,000 after buying an additional 7,737,261 shares during the period. Renaissance Technologies LLC increased its stake in OraSure Technologies by 22.3% in the first quarter. Renaissance Technologies LLC now owns 5,132,003 shares of the medical instruments supplier’s stock valued at $66,357,000 after buying an additional 934,700 shares during the last quarter. Vanguard Group Inc. increased its stake in OraSure Technologies by 30.3% in the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock valued at $57,752,000 after buying an additional 1,037,439 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in OraSure Technologies by 15.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,890,048 shares of the medical instruments supplier’s stock valued at $37,368,000 after buying an additional 395,374 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in OraSure Technologies by 127.2% in the first quarter. JPMorgan Chase & Co. now owns 1,573,586 shares of the medical instruments supplier’s stock valued at $20,347,000 after buying an additional 881,132 shares during the last quarter. Hedge funds and other institutional investors own 88.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by Mideast Time and is the sole property of of Mideast Time. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.mideasttime.com/analysts-anticipate-orasure-technologies-inc-osur-will-post-earnings-of-0-07-per-share/1790907.html.

OraSure Technologies (OSUR) traded down 1.45% during midday trading on Tuesday, reaching $14.94. The company had a trading volume of 1,115,137 shares. OraSure Technologies has a one year low of $5.57 and a one year high of $15.90. The stock has a market capitalization of $862.96 million, a price-to-earnings ratio of 28.62 and a beta of 1.60. The company has a 50-day moving average price of $14.85 and a 200-day moving average price of $11.52.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:OSUR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.